Prime Medicine PRME Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One at other companies
Other financials
Where this comes from
Reported directly by Prime Medicine in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue.
The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Prime Medicine's debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Prime Medicine's debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one?
- Prime Medicine (PRME) reported debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one of $71.39M in Q1 2026.
- How has Prime Medicine's debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one changed year-over-year?
- Prime Medicine's debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one increased by 47.3% year-over-year, from $48.47M to $71.39M.
- What is the long-term trend for Prime Medicine's debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one?
- Over 4 years (2021 to 2025), Prime Medicine's debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one has grown at a 13.9% compound annual growth rate (CAGR), from $68.24M to $114.65M.